IP Library Granted Patent US 12697400
Granted Patent B2
US 12697400 · App. 18/702,749 · Granted Aug 4, 2026

Gene editing methods for treating alpha-1 antitrypsin (AAT) deficiency

Inventors: James Jefferson Smith (Morrisville, NC); John Morris (Raleigh, NC); Janel Lape (Wake Forest, NC); Cassandra Gorsuch (Hillsborough, NC); Paige Scarlett Nemec (Durham, NC); Jason Richard Harris (Durham, NC); Wendy Shoop (Durham, NC)
Assignee: Precision BioSciences, Inc.
A61K48/0058A61K9/127A61K9/5123A61K38/57A61P5/00C12N9/22C12N15/86C12N15/88C12N15/907C12N2750/14143C12N2830/008C12N2830/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12697400
App. No.
18/702,749
Granted
Aug 4, 2026
Kind
B2
Abstract

Disclosed are engineered meganucleases that bind and cleave a recognition sequence within a serine peptidase inhibitor, Clade A, Member 1 (SERPINA1) gene, which encodes alpha-1 antitrypsin (AAT). Further disclosed are donor polynucleotides that encode functional AAT proteins. The present disclosure also encompasses methods of using such engineered meganucleases and donor polynucleotides to make genetically-modified cells and use of such compositions for treatment of AAT deficiency.

Claims (4)

1 . An engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 9 within a SERPINA1 gene, wherein said engineered meganuclease comprises a first subunit and a second subunit, wherein said first subunit binds to a first recognition half-site of said recognition sequence and comprises a first hypervariable (HVR1) region, and wherein said second subunit binds to a second recognition half-site of said recognition sequence and comprises a second hypervariable (HVR2) region, wherein said engineered meganuclease comprises the amino acid sequence of any one of SEQ ID NOs: 17-22.

2 . An engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 11 within a SERPINA1 gene, wherein said engineered meganuclease comprises a first subunit and a second subunit, wherein said first subunit binds to a first recognition half-site of said recognition sequence and comprises a first hypervariable (HVR1) region, and wherein said second subunit binds to a second recognition half-site of said recognition sequence and comprises a second hypervariable (HVR2) region, wherein said engineered meganuclease comprises the amino acid sequence of any one of SEQ ID NOs: 41-46.

3 . An engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 13 within a SERPINA1 gene, wherein said engineered meganuclease comprises a first subunit and a second subunit, wherein said first subunit binds to a first recognition half-site of said recognition sequence and comprises a first hypervariable (HVR1) region, and wherein said second subunit binds to a second recognition half-site of said recognition sequence and comprises a second hypervariable (HVR2) region, wherein said engineered meganuclease comprises the amino acid sequence of any one of SEQ ID NOs: 65-71.

4 . An engineered meganuclease that binds and cleaves a recognition sequence comprising SEQ ID NO: 15 within a SERPINA1 gene, wherein said engineered meganuclease comprises a first subunit and a second subunit, wherein said first subunit binds to a first recognition half-site of said recognition sequence and comprises a first hypervariable (HVR1) region, and wherein said second subunit binds to a second recognition half-site of said recognition sequence and comprises a second hypervariable (HVR2) region, wherein said engineered meganuclease comprises the amino acid sequence of any one of SEQ ID NOs: 93-100.